Study on Metallo-Beta Lactamase Producing Pseudomonas Species in Clinical Isolates of a Tertiary Care Hospital of Western Odisha.

Corresponding Author:
Suchitra Mishra,
Department of Microbiology,
Hitech Medical College,
Rourkela, Odisha, India.
E-mail: shmu963@gmail.com

ABSTRACT

BACKGROUND

Pseudomonas species are responsible for 10% of hospital acquired infection especially in an ICU set up and in burn patients. Metallo-beta lactamase production is the most common mechanism of resistance to carbapenem which is the most commonly used drug to treat Pseudomonas. Local prevalence of MBL producing Pseudomonas is important information to both microbiologist and clinician to formulate hospital infection control strategy. This cross-sectional descriptive study was conducted in a tertiary care hospital of western Odisha to detect MBL prevalence among clinical isolates of Pseudomonas species.

METHODS

187 Pseudomonas strains (165 P. aeruginosa and 22 P. putida) isolated in different clinical samples in Vitek 2 system were checked for imipenem resistance (MIC>8 µl/ml). All imipenem resistance strains were checked for MBL production by combined disc test with imipenem, and MBL production was confirmed by MBL E test.

RESULTS

Among 187 Pseudomonas strains 12.20% were carbapenem resistant and 9% were MBL producing. About 74% of carbapenem resistant Pseudomonas strains were MBL positive. MBL positivity rate was much higher in Pseudomonas putida (27.20%) compared to Pseudomonas aeruginosa (7%) and in ICU (14.20%) compared to IPD (9.20%) or OPD (6.80%). Colistin was the most effective (97%) antibiotic against MBL producing Pseudomonas.

CONCLUSIONS

It is better to prevent MBL Pseudomonas than to cure it as most of the antibiotics were found to be ineffective against it. In our study MBL production rate in clinical isolate of Pseudomonas was low (9%) compared to other studies in India.

KEY WORDS

Pseudomonas, Carbapenem, MBL, Positivity.